Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised re… - SLUB Dresden

Medientyp: E-Artikel

Titel: Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS) : Part I: diagnosis and differential diagnosis

Beteiligte: Jarius, Sven [Verfasser:in]; Aktas, Orhan [Verfasser:in]; Ayzenberg, Ilya [Verfasser:in]; Bellmann-Strobl, Judith [Verfasser:in]; Berthele, Achim [Verfasser:in]; Giglhuber, Katrin [Verfasser:in]; Häußler, Vivien [Verfasser:in]; Havla, Joachim [Verfasser:in]; Hellwig, Kerstin [Verfasser:in]; Hümmert, Martin W. [Verfasser:in]; Kleiter, Ingo [Verfasser:in]; Klotz, Luisa [Verfasser:in]; Krumbholz, Markus [Verfasser:in]; Kümpfel, Tania [Verfasser:in]; Paul, Friedemann [Verfasser:in]; Ringelstein, Marius [Verfasser:in]; Ruprecht, Klemens [Verfasser:in]; Senel, Makbule [Verfasser:in]; Stellmann, Jan-Patrick [Verfasser:in]; Bergh, Florian Then [Verfasser:in]; Tumani, Hayrettin [Verfasser:in]; Wildemann, Brigitte [Verfasser:in]; Trebst, Corinna [Verfasser:in]

Erschienen: 6 April 2023

Sprache: Englisch

DOI: 10.1007/s00415-023-11634-0

Identifikator:

Schlagwörter: Aquaporin-4 (AQP4) ; Autoantibodies ; Cerebrospinal fluid (CSF) ; Clinical presentation ; Diagnosis ; Diagnostic criteria ; Differential diagnosis ; Magnetic resonance imaging (MRI) ; MOG antibody-associated disease (MOGAD) ; MOG antibody-associated encephalomyelitis (MOG-EM) ; Myelin oligodendrocyte glycoprotein (MOG) ; Myelitis ; Neuromyelitis optica (NMO) ; Neuromyelitis optica spectrum disorders (NMOSD) ; Optic coherence tomography (OCT) ; Optic neuritis ; Serology

Entstehung:

Anmerkungen:

Beschreibung: The term ‘neuromyelitis optica spectrum disorders’ (NMOSD) is used as an umbrella term that refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) and its formes frustes and to a number of closely related clinical syndromes without AQP4-IgG. NMOSD were originally considered subvariants of multiple sclerosis (MS) but are now widely recognized as disorders in their own right that are distinct from MS with regard to immunopathogenesis, clinical presentation, optimum treatment, and prognosis. In part 1 of this two-part article series, which ties in with our 2014 recommendations, the neuromyelitis optica study group (NEMOS) gives updated recommendations on the diagnosis and differential diagnosis of NMOSD. A key focus is on differentiating NMOSD from MS and from myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD), which shares significant similarity with NMOSD with regard to clinical and, partly, radiological presentation, but is a pathogenetically distinct disease. In part 2, we provide updated recommendations on the treatment of NMOSD, covering all newly approved drugs as well as established treatment options.

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: